$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: MGRM, EPIX, BLBX, and PBBK
Monogram Technologies Inc. (NASDAQ: MGRM) related to its sale to Zimmer Biomet Holdings, Inc. Under the terms of the proposed transaction, Monogram shareholders would receive an upfront payment of $4.04 per share in cash, and one non-tradeable contingent value right collectively worth up to $12.37 per share in cash payable (i) $1.04 upon completion of a proof-of-concept demonstration of Monogram's robotic system for unicompartmental (partial) knee arthroplasty made available to Zimmer's designated executives on or before the later January 31, 2026 or 30 days following the Closing; (ii) $1.08 upon the grant of 510(k) clearance by the FDA for Monogram's fully autonomous robotic system for use with Zimmer implants, as evidenced by formal clearance indicating substantial equivalence to a predicate device, on or before December 31, 2027; (iii) $3.41 when the company achieves gross revenue of at least $156 million between January 1, 2028 and December 31, 2028; (iv) $3.41 when the company achieves gross revenue of at least $381 million between January 1, 2029 and December 31, 2028; and (v) $3.43 when the company achieves gross revenue of at least $609 million between January 1, 2030 and December 31, 2030.
Click here for more information https://monteverdelaw.com/case/monogram-technologies-inc/. It is free and there is no cost or obligation to you.
ESSA Pharma Inc. (NASDAQ: EPIX) related to its sale to Xeno Acquisition Corp. Upon completion of the transaction, ESSA shareholders will receive a cash payment per share to be calculated based upon ESSA's cash balance at closing minus transaction costs, liability and legal exposure review, and a $4 million transaction fee payable to Xeno. Additionally, ESSA shareholders are entitled to receive one non-transferable contingent value right per share entitling them to future payments based on (i) up to $150,000.00, less any remaining liabilities and expenses not deducted at closing; and (ii) up to $2.8 million, less legal and other expenses incurred after closing.
Click here for more information https://monteverdelaw.com/case/essa-pharma-inc/. It is free and there is no cost or obligation to you.
Blackboxstocks Inc. (NASDAQ: BLBX), relating to the proposed merger with REalloys Inc. Under the terms of the agreement, it is anticipated Blackbox's stockholders will own approximately 7.3% of the combined company's common stock.
Click here for more information https://monteverdelaw.com/case/blackboxstocks-inc-blbx/. It is free and there is no cost or obligation to you.
PB Bankshares Inc. (NASDAQ: PBBK) related to its sale to Norwood Financial Corp. Under the terms of the proposed transaction, PB Bankshares' shareholders will have the option to elect to receive either 0.7850 shares of Norwood common stock or $19.75 in cash for each common share of PB Bankshares they own. The election is subject to proration to ensure that, in the aggregate, 80% of the transaction consideration will be paid in the form of Norwood common stock.
Click here for more information https://monteverdelaw.com/case/pb-bankshares-inc/. It is free and there is no cost or obligation to you.
NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask:
Do you file class actions and go to Court?
When was the last time you recovered money for shareholders?
What cases did you recover money in and how much?
About Monteverde & Associates PC
Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.
No company, director or officer is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.
Contact:Juan Monteverde, Esq.MONTEVERDE & ASSOCIATES PCThe Empire State Building350 Fifth Ave. Suite 4740New York, NY 10118United States of Americajmonteverde@monteverdelaw.comTel: (212) 971-1341
Attorney Advertising. (C) 2025 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
3 hours ago
- New Straits Times
MCE eyes growth on Perodua EV, US expansion: HLIB
KUALA LUMPUR: MCE Holdings Bhd is set to enter a multi-year growth phase on the back of a landmark Perodua electric vehicle (EV) contract and expansion into the United States, according to Hong Leong Investment Bank (HLIB) Research. HLIB Research has initiated coverage on MCE with a "Buy" call and a target price of RM2.40, valuing the stock at 15 times its mid-FY27 partially diluted earnings per share of 16 sen. The firm described the auto parts supplier as a resilient, scalable play on Malaysia's shift towards high-value automotive electronics and the global 'China + N' supply chain realignment. MCE's entry into the EV segment comes through a high-value contract with Perodua to supply infotainment and advanced driver assistance system (ADAS) components, with revenue per vehicle at around RM3,000, about ten times its typical value. "With Perodua targeting an affordable launch price, we estimate MCE's annual revenue from this programme could amount to between RM39.8 million and RM59.7 million annually, or 26 per cent to 38 per cent of FY24 revenue, making it a powerful earnings catalyst," HLIB Research said. HLIB Research added that the company is accelerating its global expansion with two US wins for Nasdaq-listed Dorman in the automotive aftermarket and Michigan-based JVIS, a supplier to major original equipment manufacturers. The firm said the JVIS deal involves two multi-year mechatronics supply contracts worth RM91.7 million over five years, adding about RM18.3 million annually. Beyond automotive, MCE is expanding into new growth areas via multiple joint ventures, including a tie-up with Hong Kong's Sounding Industries to produce non-automotive products at its Johor facilities. The company also partnered with China's Nanjing Chuhang to produce ADAS mmWave radars at its upcoming Serendah plant, along with Chery-linked suppliers Cheling and Atech for participation in Chery's Malaysian localisation programme. MCE also formed a joint venture with India's Abhishek Electronics to tap into the fast-growing Indian automotive market. HLIB Research projects MCE's core earnings to grow at a compound annual growth rate of 15.8 per cent with estimated earnings for FY25, FY26 and FY27 reaching RM20.2 million, RM21.4 million and RM27 million, respectively. "FY26 growth will be driven by contribution from Dorman and the non-auto segment starting in the first half of FY26, with a stronger lift in the second half from Perodua's EV supply. "FY27 will see the full-year EV impact, maiden JVIS contribution and scaling of Dorman and non-auto has a robust balance sheet with a net cash position of RM83.6 million, equivalent to 59.8 sen a share, around 42 per cent of market capitalisation," the firm added. HLIB Research said years of investment in engineering and technology now position MCE to ride structural shifts in Malaysia's automotive industry towards localisation, high-value electronics and EV adoption, while benefiting from global supply chain diversification. It added that the company offers a resilient, scalable play on the sector's long-term transformation, anchored by stable demand from Proton and Perodua, as well as expansion via high-margin electronics, exports and strategic JVs.
New Straits Times
4 hours ago
- New Straits Times
Shares edge up in Asia, US inflation data looms large
SYDNEY: Major share indexes crept higher in Asia on Monday as upbeat company earnings underpinned high valuations in the tech sector, while a crucial report on US inflation would likely set the course of the dollar and bonds. Trade and geopolitics also loom large with a US tariff deadline on China due to expire on Tuesday amid expectations it will get extended again, while President Donald Trump and Russian leader Vladimir Putin are due to meet in Alaska on Friday to discuss Ukraine. The main economic release will be US consumer prices on Tuesday, with analysts expecting the impact of tariffs to help nudge the core up 0.3 per cent to an annual pace of 3.00 per cent and away from the Federal Reserve target of 2.00 per cent. An upside surprise would challenge market wagers for a September rate cut, though analysts assume it would have to be a very high number given a downward turn in payrolls is now dominating the outlook. "The tone from the Fed has shifted as a number of officials expressed concerns about growth following the July employment report," said Bruce Kasman, chief economist at JPMorgan. "We now expect the Fed to restart its easing cycle in September," he added. "Recession risks are elevated at 40 per cent, but we do not yet see a case for a larger than 25bp series of cuts." Markets imply around a 90 per cent probability of a September easing, and at least one more cut by year end. Trump's pick for Fed governor, Stephen Miran, may or may not be in place in time to vote for a cut in September, while the choice of a new chair has broadened out to around 10 contenders. The prospect of lower borrowing costs has supported equities, along with a run of strong earnings. Analysts at BofA note 73 per cent of companies had beaten on earnings, well above the 59 per cent long run average, while 78 per cent beat on revenue. "While mentions of 'weak demand' ticked up and tariff concerns remain, corporate sentiment and guidance are improving," they said in a note. S&P 500 futures and Nasdaq futures both edged up 0.1 per cent to near record highs. Analysts were unsure what to make of a report in the Financial Times that tech majors Nvidia and AMD have agreed to give the US government 15 per cent of their revenues from chip sales in China, under an arrangement to obtain export licences for the semiconductors. Japan's stock market was closed for a holiday, but futures stood at 42,290 and well above the cash close of 41,820, suggesting the index could test its all-time high of 42,426 this week. MSCI's broadest index of Asia-Pacific shares outside Japan was a fraction firmer, while South Korea was flat having bounced 2.9 per cent last week. EUROSTOXX 50 futures added 0.2 per cent, while FTSE futures were flat and DAX futures firmed 0.3 per cent. Currencies were quiet with markets thinned by Japan's absence, with the dollar index steady at 98.246 after slipping 0.4 per cent last week. The euro was flat at US$1.1644 and comfortably above its recent trough of US$1.1392, while the dollar held at 147.66 yen having met resistance around 147.90. The Australian dollar eased to US$0.6516 ahead of a meeting of the Reserve Bank of Australia which is widely expected to sanction a rate cut, having stunned markets in July by skipping an easing to await more inflation data. The figures turned out benign, so investors have again fully priced a quarter-point cut to 3.60 per cent. In commodity markets, gold dipped 0.3 per cent to US$3,386.00 an ounce after wild swings last week on reports the US would slap 39 per cent tariffs on some gold bars, which are major exports of Switzerland. Gold futures pared gains on Friday when the White House said it planned to issue an executive order clarifying the country's stance on gold bar tariffs. Oil prices slipped amid risks the talks between Trump and Putin could make progress to a ceasefire in Ukraine and possibly an eventual easing of sanctions on Russian oil exports. Brent dropped 0.6 per cent to US$66.22 a barrel, while US crude eased 0.7 per cent to US$63.44 per barrel.
Malaysian Reserve
8 hours ago
- Malaysian Reserve
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Aug. 10, 2025 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. ('Altimmune' or 'the Company') (NASDAQ: ALT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Altimmune securities between August 10, 2023 and June 25, 2025, both dates inclusive (the 'Class Period'). Such investors are encouraged to join this case by visiting the firm's site: Case Details The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Altimmune's IMPACT Phase 2b MASH trial of Pemvidutide was unlikely to achieve statistical significance in its primary endpoint of fibrosis reduction due to inflated expectations and flawed trial design; (2) the Company's public statements regarding the efficacy of Pemvidutide and the likelihood of regulatory success were overly optimistic and lacked a reasonable basis; (3) Defendants downplayed the significance of the trial's failure to meet statistical significance, attributing the result to the Phase 2 nature of the study and suggesting better outcomes in a future Phase 3 trial; and (4) as a result, Defendants' statements about the Company's business, operations, and prospects were materially false and misleading at all relevant times. What's Next? A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Altimmune you have until October 6, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. There is No Cost to You We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful. Why Bronstein, Gewirtz & Grossman Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. Follow us for updates on LinkedIn, X, Facebook, or Instagram. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Bronstein, Gewirtz & Grossman, LLCPeretz Bronstein or Nathan Miller332-239-2660 | info@
